ABBOTT PARK, Ill., Jan. 17, 2017
/PRNewswire/ -- New data published in the January edition of
Pain has confirmed the superiority of Abbott's dorsal root
ganglion (DRG) stimulation therapy over traditional spinal cord
stimulation (SCS) for patients suffering from complex regional pain
syndrome (CRPS). The data, which include both short-term and
long-term data from the ACCURATE study, also suggested that DRG
stimulation benefits patients' total mood and activity levels.
Abbott is the only company in the world approved to offer DRG
stimulation.
While the latest publication highlights the superiority of
Abbott's DRG stimulation therapy for patients suffering from CRPS,
real-world insight also continues to support momentum around
adoption of the therapy among providers offering DRG stimulation to
their patients. Since the company launched DRG stimulation in
April 2016 in the United States, more than 300 physicians
across the country have been trained to deliver the therapy. The
therapy is now offered in every state in the U.S., and has been
widely available in Europe since
2011.
"Historically, many patients with chronic pain resulting from
complex regional pain syndrome or pain resulting from damage to
peripheral nerves report inconsistent or inadequate pain relief
from tonic spinal cord stimulation. As a physician this is
frustrating because our ultimate goal is to deliver options
providing meaningful pain relief," said Timothy R. Deer, M.D., president and chief
executive officer of The Center for Pain Relief in Charleston, West Virginia, and lead author of
the ACCURATE study publication. "The findings highlighted in our
publication align with what I've seen in my practice since U.S.
approval of DRG stimulation: that DRG stimulation offers a superior
option for CRPS-related chronic pain and improved quality of life
for my patients."
Findings from the ACCURATE Study
The latest publication in Pain highlights both
three-month and 12-month data from the ACCURATE study, the largest
study to date evaluating patients suffering from chronic lower limb
pain associated with CRPS. The 12-month data were previously
presented at the 19th annual meeting of the North American
Neuromodulation Society (NANS) in Las
Vegas, Nevada, in December
2015 and the three-month primary endpoint data were
originally presented at the International Neuromodulation Society
(INS) annual meeting in June
2015.
The ACCURATE study showed that after both three and 12 months,
Abbott's DRG stimulation therapy offered patients:
- Sustained and superior pain relief: After 12
months, a statistically significant number of patients receiving
DRG stimulation achieved meaningful pain relief and greater
treatment success when compared to patients receiving traditional
SCS (74.2 percent vs. 53.0 percent).
Secondary endpoint data suggested:
- Reduced paresthesia: At 12 months, more than a
third of patients who received DRG stimulation were experiencing
greater than 80 percent pain relief with no paresthesia.
(Paresthesia is a light tingling sensation often accompanying
traditional tonic spinal cord stimulation.)
- Improvements in quality of life: At 12 months, DRG
patients had statistically greater improvements in their physical
component (p=0.04), general health (p=0.03) and
social functioning (p=0.03) when compared to SCS
subjects.
"Data such as these are critical to providing patients hope that
there are treatment options out there that can provide meaningful
pain relief for the excruciating pain CRPS sufferers deal with
every day," said Jim Broatch,
executive vice president and director of the Reflex Sympathetic
Dystrophy Syndrome Association (RSDSA), a group specializing in
providing resources for patients battling CRPS. "Our organization,
which has focused for years on advancing treatments for patients
with CRPS, applauds the physicians and patients who took part in
this study and who have helped advance the understanding of this
condition and the impact of DRG stimulation on improving the lives
of patients everywhere."
Patients battling CRPS often face prolonged or excessive chronic
pain following an injury or trauma. The condition is believed to be
caused in part by damaged or malfunctioning nerves, and it affects
the way the central and peripheral nervous systems transmit and
receive pain signals. Stimulation with Abbott's Axium®
Neurostimulation System targets nerves within the DRG, a spinal
structure made up of sensory nerves. DRG stimulation has been
clinically-proven to provide pain relief directly to the area of
the body where pain occurs.
About Abbott's Chronic Pain Portfolio:
Chronic pain affects approximately 1.5 billion people worldwide,
more than heart disease, cancer and diabetes combined. The
condition can negatively impact personal relationships, work
productivity and a patient's daily routine. Abbott is a global
leader in the development of chronic pain therapy solutions and the
only medical device manufacturer in the world to offer
radiofrequency ablation (RFA) and spinal cord stimulation (SCS)
therapy solutions including BurstDR stimulation and stimulation of
the dorsal root ganglion (DRG) for the treatment of chronic
pain.
About Abbott:
At Abbott (NYSE: ABT), we're committed to helping people live
their best possible life through the power of health. For more than
125 years, we've brought new products and technologies to the world
-- in nutrition, diagnostics, medical devices and branded generic
pharmaceuticals -- that create more possibilities for more people
at all stages of life. Today, 74,000 of us are working to help
people live not just longer, but better, in the more than 150
countries we serve.
Connect with us at www.abbott.com, on Facebook
at www.facebook.com/Abbott and on Twitter @AbbottNews and
@AbbottGlobal.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/new-data-confirms-abbotts-dorsal-root-ganglion-stimulation-offers-greater-treatment-success-over-traditional-spinal-cord-stimulation-300391537.html
SOURCE Abbott